Current status and prospect of translational medicine in nanotechnology.
- Author:
Guang-yu GAO
;
Mei-ling CHEN
;
Ming-yuan LI
;
Zhen-bo YANG
;
Zhi-ping LI
;
Xing-guo MEI
- Publication Type:Journal Article
- MeSH:
Biocompatible Materials;
Nanostructures;
toxicity;
Nanotechnology;
Translational Medical Research
- From:
Acta Pharmaceutica Sinica
2015;50(8):919-924
- CountryChina
- Language:Chinese
-
Abstract:
Nowadays, nanotechnologies have shown wide application foreground in the biomedical field of medicine laboratory tests, drug delivery, gene therapy and bioremediation. However, in recent years, nanomaterials have been labeled poisonous, because of the disputes and misunderstandings of mainstream views on their safety. Besides, for the barriers of technical issues in preparation like: (1) low efficacy (poor PK & PD and low drug loading), (2) high cost (irreproducibility and difficulty in scale up), little of that research has been successfully translated into commercial products. Currently, along with the new theory of "physical damage is the origin of nanotoxicity", biodegradability and biocompatibility of nanomaterials are listed as the basic principle of safe application of nanomaterials. Combining scientific design based on molecular level with precision control of process engineering will provide a new strategy to overcome the core technical challenges. New turning point of translational medicine in nanotechnology may emerge.
